Corcept Therapeutics

CORT86

High Quality

$54.23arrow_drop_up3.98%$2.07

High Quality

High Growth

CORT86

$54.23

arrow_drop_up3.98%$2.07

High Quality

High Growth

Performance History

Key Stats
Open	$54.08
Prev. Close	$52.14
EPS	1.31
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

	LOW	HIGH
Day Range	52.32	56.19
52 Week Range	20.84	56.19

Ratios







EPS	1.31

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Corcept Therapeutics (CORT)

Corcept Therapeutics Inc (CORT) is a pharmaceutical company that specializes in the development and commercialization of drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders. The company focuses on discovering and developing small molecule drugs that selectively modulate the effects of cortisol. Corcept's lead product, Korlym, is an oral medication that is approved for the treatment of hyperglycemia in patients with endogenous Cushing's syndrome. The company is also conducting clinical trials to evaluate the use of Korlym in the treatment of various types of cancer, including ovarian, lung, and pancreatic cancer.

In terms of stock performance, Corcept Therapeutics Inc has had a relatively stable history. Over the past five years, the stock price has fluctuated between a low of $7.50 and a high of $25.00. Currently, the stock is trading around $15.00. The market capitalization of Corcept Therapeutics Inc is approximately $1.5 billion. The company has a PEG ratio of 1.42, indicating that the stock may be slightly overvalued compared to its industry peers. However, it is important to note that the biopharmaceutical industry as a whole tends to have higher valuations due to the high-risk nature of drug development. Corcept Therapeutics Inc is also trading below its 52-week high of $24.00, suggesting that there may be potential for price appreciation in the future.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Joseph K. Belanoff M.D.
Headquarters: Menlo Park
Employees: 299
Exchange: NASDAQ

Keep an eye on Corcept Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Corcept Therapeutics 's (CORT) price per share?

The current price per share for Corcept Therapeutics (CORT) is $54.23. The stock has seen a price change of $2.08 recently, indicating a 3.99% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Corcept Therapeutics (CORT)?

For Corcept Therapeutics (CORT), the 52-week high is $56.2, which is 3.62% from the current price. The 52-week low is $20.84, the current price is 160.22% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Corcept Therapeutics (CORT) a growth stock?

Corcept Therapeutics (CORT) has shown an average price growth of -1.92% over the past three years. It has received a score of 86 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Corcept Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Corcept Therapeutics (CORT) stock price performance year to date (YTD)?

As of the latest data, Corcept Therapeutics (CORT) has a year-to-date price change of 124.46%. Over the past month, the stock has experienced a price change of 21.43%. Over the last three months, the change has been 58.52%. Over the past six months, the figure is 126.24%. Looking at a longer horizon, the five-year price change stands at 280.56%.

help

Is Corcept Therapeutics (CORT) a profitable company?

Corcept Therapeutics (CORT) has a net income of $106.14M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 25.53% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $482.38M, with a revenue growth rate of 20.04%, providing insight into the company's sales performance and growth. The gross profit is $475.89M. Operating income is noted at $107.28M. Furthermore, the EBITDA is $144.86M.

help

What is the market capitalization of Corcept Therapeutics (CORT)?

Corcept Therapeutics (CORT) has a market capitalization of $5.65B. The average daily trading volume is 54.19, indicating the stock's liquidity and investor engagement.